Suppr超能文献

促炎 HLA-DRB1*01 单倍型易患 ST 段抬高型心肌梗死。

Proinflammatory HLA-DRB1*01-haplotype predisposes to ST-elevation myocardial infarction.

机构信息

Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland.

出版信息

Atherosclerosis. 2012 Apr;221(2):461-6. doi: 10.1016/j.atherosclerosis.2012.01.024. Epub 2012 Jan 20.

Abstract

BACKGROUND

Major histocompatibility complex (MHC) gene region harbours haplotypes that associate with coronary artery disease (CAD). Their role in ST-elevation infarction (STEMI) or on the inflammatory level is not known.

METHODS

Four candidate MHC markers were analyzed by real-time quantitative PCR and constructed into haplotypes from patients with STEMI (n = 162), matched controls with no CAD (n = 319) and general population sample (n = 149). High sensitivity C-reactive protein (hsCRP) was assessed in a follow-up visit from patients (n = 86) and at inclusion from other study subjects.

RESULTS

The haplotype with one copy of HLA-DRB101, C4A, C4B but no HLA-B35 doubled the risk of STEMI (OR = 2.15, 95%CI = 1.11-4.15, p = 0.020 for patients vs. controls, and OR = 2.26, 95%CI = 0.97-5.24, p = 0.052 for patients vs. population sample). The association between patients and controls persisted in multivariate analyses. The frequency of the haplotype was 5.86% (n = 19/324) in patients, 2.82% (n = 18/638) in controls and 2.68% (n = 8/298) in population sample. None of the individual MHC markers alone showed significant association with STEMI. In multivariate analyses, the haplotype carriers had higher hsCRP levels in patients (median 3.37 mg/L in carriers vs. 1.14 mg/L in non-carriers, p = 0.019) and in controls (median 2.90 mg/L vs. 1.21 mg/L, p = 0.009, respectively).

CONCLUSION

The MHC haplotype associates with STEMI and elevated baseline hsCRP levels. The results are in concordance with previous data on non-STEMI patients, implying that a HLA-DRB1*01--related haplotype increases the risk of CAD, possibly though increased inflammation.

摘要

背景

主要组织相容性复合体(MHC)基因区域含有与冠状动脉疾病(CAD)相关的单倍型。它们在 ST 段抬高型心肌梗死(STEMI)或炎症水平中的作用尚不清楚。

方法

通过实时定量 PCR 分析了 4 个候选 MHC 标志物,并从 STEMI 患者(n=162)、无 CAD 的匹配对照(n=319)和一般人群样本(n=149)中构建成单倍型。在随访时(n=86)和纳入时(n=其他研究对象)评估了高敏 C 反应蛋白(hsCRP)。

结果

携带一个 HLA-DRB101、C4A、C4B 但无 HLA-B35 拷贝的单倍型使 STEMI 的风险增加了一倍(OR=2.15,95%CI=1.11-4.15,p=0.020,患者与对照组相比;OR=2.26,95%CI=0.97-5.24,p=0.052,患者与人群样本相比)。多变量分析中,患者与对照组之间的关联仍然存在。该单倍型在患者中的频率为 5.86%(n=19/324),在对照组中为 2.82%(n=18/638),在人群样本中为 2.68%(n=8/298)。单独的 MHC 标志物均与 STEMI 无显著关联。多变量分析中,携带该单倍型的患者(携带者中位 hsCRP 水平为 3.37mg/L,而非携带者为 1.14mg/L,p=0.019)和对照组(携带者中位 hsCRP 水平为 2.90mg/L,而非携带者为 1.21mg/L,p=0.009)的 hsCRP 水平均较高。

结论

MHC 单倍型与 STEMI 和基线 hsCRP 水平升高相关。这些结果与先前非 STEMI 患者的数据一致,表明 HLA-DRB1*01 相关的单倍型增加了 CAD 的风险,可能是通过增加炎症。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验